Farther Finance Advisors LLC Has $56,000 Holdings in Maravai LifeSciences Holdings, Inc. (NASDAQ:MRVI)

Farther Finance Advisors LLC lifted its stake in shares of Maravai LifeSciences Holdings, Inc. (NASDAQ:MRVI) by 3,541.4% in the 4th quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm owned 10,196 shares of the company’s stock after buying an additional 9,916 shares during the quarter. Farther Finance Advisors LLC’s holdings in Maravai LifeSciences were worth $56,000 as of its most recent filing with the Securities & Exchange Commission.

Other large investors also recently modified their holdings of the company. Wealthfront Advisers LLC bought a new position in shares of Maravai LifeSciences in the 4th quarter worth $1,046,000. Atria Investments Inc acquired a new position in shares of Maravai LifeSciences during the fourth quarter valued at about $58,000. Victory Capital Management Inc. increased its position in shares of Maravai LifeSciences by 65.1% during the fourth quarter. Victory Capital Management Inc. now owns 96,273 shares of the company’s stock worth $525,000 after acquiring an additional 37,946 shares in the last quarter. VELA Investment Management LLC raised its holdings in shares of Maravai LifeSciences by 54.5% in the 4th quarter. VELA Investment Management LLC now owns 148,112 shares of the company’s stock worth $807,000 after acquiring an additional 52,246 shares during the last quarter. Finally, Y Intercept Hong Kong Ltd lifted its position in Maravai LifeSciences by 155.9% in the 4th quarter. Y Intercept Hong Kong Ltd now owns 32,359 shares of the company’s stock valued at $176,000 after acquiring an additional 19,713 shares in the last quarter. Institutional investors and hedge funds own 50.25% of the company’s stock.

Analyst Upgrades and Downgrades

MRVI has been the subject of a number of recent research reports. UBS Group decreased their price objective on Maravai LifeSciences from $8.00 to $2.50 and set a “neutral” rating for the company in a report on Friday. Bank of America dropped their price objective on Maravai LifeSciences from $9.00 to $8.00 and set a “buy” rating on the stock in a research note on Monday, March 3rd. Robert W. Baird lowered shares of Maravai LifeSciences from an “outperform” rating to a “neutral” rating and reduced their target price for the stock from $9.00 to $3.00 in a research note on Wednesday, February 26th. Baird R W downgraded shares of Maravai LifeSciences from a “strong-buy” rating to a “hold” rating in a report on Wednesday, February 26th. Finally, The Goldman Sachs Group cut shares of Maravai LifeSciences from a “neutral” rating to a “sell” rating and cut their price target for the stock from $7.00 to $4.25 in a report on Thursday, December 5th. One equities research analyst has rated the stock with a sell rating, seven have given a hold rating and four have issued a buy rating to the company. Based on data from MarketBeat, the stock has an average rating of “Hold” and a consensus price target of $8.22.

Insiders Place Their Bets

In other Maravai LifeSciences news, General Counsel Kurt Oreshack sold 25,000 shares of the company’s stock in a transaction dated Friday, January 31st. The shares were sold at an average price of $5.03, for a total transaction of $125,750.00. Following the transaction, the general counsel now owns 167,618 shares in the company, valued at approximately $843,118.54. This represents a 12.98 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Corporate insiders own 0.63% of the company’s stock.

Maravai LifeSciences Price Performance

Shares of MRVI opened at $2.27 on Friday. The firm’s 50-day simple moving average is $3.96 and its two-hundred day simple moving average is $5.81. Maravai LifeSciences Holdings, Inc. has a fifty-two week low of $2.07 and a fifty-two week high of $11.56. The stock has a market cap of $573.24 million, a PE ratio of -1.38 and a beta of -0.08. The company has a debt-to-equity ratio of 0.89, a quick ratio of 9.94 and a current ratio of 10.74.

Maravai LifeSciences Company Profile

Maravai LifeSciences Holdings, Inc, a life sciences company, provides products to enable the development of drug therapies, diagnostics, novel vaccines, and support research on human diseases worldwide. The company’s products address the key phases of biopharmaceutical development and include nucleic acids for diagnostic and therapeutic applications, antibody-based products to detect impurities during the production of biopharmaceutical products, and products to detect the expression of proteins in tissues of various species.